These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 27004367)

  • 1. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
    Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
    Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease].
    Qiao S; Luo JH; Jin JH
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.
    Hoenen C; Gustin A; Birck C; Kirchmeyer M; Beaume N; Felten P; Grandbarbe L; Heuschling P; Heurtaux T
    PLoS One; 2016; 11(9):e0162717. PubMed ID: 27622765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
    Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
    Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
    Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
    FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease.
    Pradhan S; Andreasson K
    Exp Neurol; 2013 Mar; 241():148-55. PubMed ID: 23261765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-let-7a suppresses α-Synuclein-induced microglia inflammation through targeting STAT3 in Parkinson's disease.
    Zhang J; Dongwei Zhou ; Zhang Z; Xinhui Qu ; Kunwang Bao ; Guohui Lu ; Jian Duan
    Biochem Biophys Res Commun; 2019 Nov; 519(4):740-746. PubMed ID: 31547989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson's disease.
    Li Y; Niu M; Zhao A; Kang W; Chen Z; Luo N; Zhou L; Zhu X; Lu L; Liu J
    J Neuroinflammation; 2019 Dec; 16(1):263. PubMed ID: 31831012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease.
    Van der Perren A; Macchi F; Toelen J; Carlon MS; Maris M; de Loor H; Kuypers DR; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
    Neurobiol Aging; 2015 Mar; 36(3):1559-68. PubMed ID: 25660193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease.
    Olanow CW; Savolainen M; Chu Y; Halliday GM; Kordower JH
    Brain; 2019 Jun; 142(6):1690-1700. PubMed ID: 31056668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
    Rocha EM; De Miranda B; Sanders LH
    Neurobiol Dis; 2018 Jan; 109(Pt B):249-257. PubMed ID: 28400134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD.
    Chang C; Lang H; Geng N; Wang J; Li N; Wang X
    Neurosci Lett; 2013 Aug; 548():190-5. PubMed ID: 23792198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
    Zhang QS; Heng Y; Yuan YH; Chen NH
    Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological features of alpha-synuclein in Parkinson's disease.
    Roodveldt C; Christodoulou J; Dobson CM
    J Cell Mol Med; 2008 Oct; 12(5B):1820-9. PubMed ID: 18671754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.
    Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM
    Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
    Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
    Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.